Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › CytoDyn Shifts Toward Prostate Cancer Prognostic Testing With ProstaGene Acquisition

CytoDyn Shifts Toward Prostate Cancer Prognostic Testing With ProstaGene Acquisition

Oct 24, 2018
|
John Gilmore
Premium

NEW YORK (GenomeWeb) – After acquiring startup ProstaGene in August, molecular diagnostics firm CytoDyn will commercialize ProstaGene's prognostic prostate cancer assay as part of the firm's push into the cancer diagnostic market.

Vancouver, Washington-based CytoDyn believes the prognostic tool — which determines if the tumor will grow slowly or aggressively — will help stratify patients' risk for their prostate cancer outcome and help streamline clinical decisions for downstream surgery, radiation therapies, or therapeutics.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Apr
13
Featured Webinar

An Opportunity Arises from the Pandemic: The Promise of Targeted NGS for SARS-CoV-2 Detection

Sponsored by
Beckman Coulter Life Sciences

Mitigation of the SARS-CoV-2 pandemic will continue to require innovative solutions. This webinar will outline how Fry Laboratories rapidly redeployed a next-generation sequencing (NGS) pipeline originally created for the detection and identification of bacterial, eukaryotic, and fungal infections in response to SARS-CoV-2.

Apr
16
Featured Webinar

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Apr
29
Featured Webinar

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
13
Featured Webinar

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

What's Popular?

In Molecular Diagnostics

  1. CLIA Waiver in Hand, Binx Health Targeting Retailers, Urgent Care Centers With STI Tests

    Premium

  2. Hologic to Acquire Finnish MDx Firm Mobidiag for Approximately $795M

  3. Novacyt in Dispute with UK Department of Health and Social Care Over Coronavirus Test Contract

  4. Armed With $55M in New Funding, Nucleix to Further Invest in Early-Stage Lung Cancer Dx

    Premium

  5. LumiraDx to Go Public on Nasdaq Through SPAC

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.